NCT05417282
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have brain metastases visible on contrast-enhanced MRI
Exclusions: Patients with prior whole-brain radiotherapy
https://ClinicalTrials.gov/show/NCT05417282